Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. [PDF]
, 2018 Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although the immune system is known to recognize these tumor cells, one mechanism by which NSCLC can evade the immune system is via overexpression of programmed ...
Che, James +10 more
core +3 more sources
Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor
Bio-Protocol, 2023 Blockade of the programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) axis is a promising strategy for cancer immunotherapy. Although antibody-based PD-1/PD-L1 inhibitors have shown remarkable results in clinical cancer studies, their inherent ...
Tess Puopolo +6 more
doaj +1 more source
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]
, 2016 A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R +11 more
core +2 more sources
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
JCI Insight, 2022 Immune checkpoint therapy targeting the PD-1/PD-L1 axis is a potentially novel development in anticancer therapy and has been applied to clinical medicine.
Ray Sagawa +18 more
doaj +1 more source
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]
, 2017 Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman +25 more
core +3 more sources
Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. [PDF]
, 2016 BackgroundMalignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade.
Bernthal, Nicholas +11 more
core +2 more sources
The function and regulation of PD-L1 in immunotherapy
ADMET and DMPK, 2017 PD-L1, also known as B7-H1, is a type I transmembrane protein, which is expressed in different kinds of tumor cells. It is correlated with poor clinical outcome of patients with various types of tumors.
Libin Guo, Yao Lin, Hang Fai Kwok
doaj +1 more source
STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells
Cell Death and Disease, 2022 Immune checkpoint molecule programmed death-ligand 1 (PD-L1) is overexpressed in cancer cells and imparts resistance to cancer therapy. Although membrane PD-L1 has been targeted for cancer immune therapy, nuclear PD-L1 was reported to confer cancer ...
Je-Jung Lee +5 more
doaj +1 more source
Diagnostic Pathology, 2020 Background The prognostic potential of PD-L1 is currently unclear in gastric carcinomas, although the immune checkpoint PD-1/PD-L1 inhibitors have produced promising results in clinical trials.
Euno Choi +14 more
doaj +1 more source
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers [PDF]
, 2017 Blockade of the inhibitory PD-1/PD-L1 immune checkpoint axis is a promising cancer treatment. Nonetheless, a significant number of patients and malignancies do not respond to this therapy.
Breckpot, K +9 more
core +2 more sources